title: Use caution when managing paclitaxel and taxotere infiltrations.
authors.affiliation: Rush Cancer Institute, Chicago, IL, USA.
authors.forename: M
authors.initials: M
authors.lastname: Goodman
authors.forename: I
authors.initials: I
authors.lastname: Stewart
authors.forename: J
authors.initials: J
authors.lastname: Lydon
authors.forename: C
authors.initials: C
authors.lastname: Blendowski
authors.forename: M
authors.initials: M
authors.lastname: Barnicle
authors.forename: J
authors.initials: J
authors.lastname: Petersen
authors.forename: R
authors.initials: R
authors.lastname: Wickham
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000451:nursing*; D006801:Humans; D007262:Infusions, Intravenous / Q000451:nursing*; D009369:Neoplasms / Q000188:drug therapy / Q000451:nursing*; D009730:Nursing Assessment; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel